Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with O6-methylguanine DNA methyltransferase expression a case series

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 120-125

  Ferriss, J Stuart ^a   Atkins, Kristen A ^a   Lachance, Jason A ^a   Modesitt, Susan C ^a   Jazaeri, Amir A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

MGMT; Temozolomide; Uterine leiomyosarcoma

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MEGESTROL; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TAMOXIFEN; TEMOZOLOMIDE;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; GYNECOLOGICAL EXAMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGIST; PATHOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; UTERUS LEIOMYOSARCOMA; UTERUS MYOMA; UTERUS SARCOMA;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS, PHARMACOLOGICAL; DACARBAZINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 74249101716     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c7fe53     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93:204-208.
3. Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999;74: 196-201.
4. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702-1709.
5. Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol. 2003;91:209-212.
6. Dinh TA, Oliva EA, Fuller EF Jr, et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92:648-652.
7. Giuntoli RL II, Garrett-Mayer E, Bristow RE, et al. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82-88.
8. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 1988;71:845-850.
9. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808-818.
10. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626-632.
11. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109:329-334.
12. Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008;109:323-328.
13. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846-5852.
14. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis. 1992;13:1503-1507.
15. 6-alkylguanine DNA-alkyltransferase expression in human breast tumours. Br J Cancer. 2002;86:1797-1802.
16. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26:4189-4199.
17. 6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338-345.
18. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 2003;98:1942-1946.
19. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98:2693-2699.
20. Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005;104:1706-1712.
21. Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol. 2005;98:99-103.
22. Boyar MS, Hesdorffer M, Keohan ML, et al. Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. Sarcoma. 2008;2008:412503.
23. 6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24:3431-3437.
24. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88: 1004-1011.
25. 6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006;12:1577-1584.
26. Rimel BJ, Huettner P, Powell MA, et al. Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol. 2009;112:224-228.